Open Clinical Trials

 

Principal Investigator: Michael E. Bromberg, MD, PhD
Primary Contact: Nancy Brunetti

Title: A Safety And Efficacy Trial Evaluating The Use Of Apixaban In The Treatment of Symptomatic Deep Vein Thrombosis and Pulmonary Embolism. 

Diagnoses: Deep Vein Thrombosis or Pulmonary Embolism

Study Inclusion Criteria: 

  • Male or female 18 years or older
  • Patients presenting with new onset of DVT and PE

This research study has been reviewed and approved by the Temple University Institutional Review Board and is assigned IRB Protocol #12262.

If you wish to be contacted regarding this study, please email cancer@tuhs.temple.edu and refer to study #12262.

    

Principal Investigator: Michael E. Bromberg, MD, PhD
Primary Contact: Thomas Parsons

Title: A randomized, double blind, placebo controlled study evaluating the efficacy & safety of romiplostim treatment of thrombocytopenia in subjects with low or intermediate-1 risk Myelodysplastic Syndrome (MDS).  Amgen.

Diagnoses: Low or intermediate risk myelodysplastic syndrome

Study Inclusion Criteria:

  • Male or female 18 years or older
  • Diagnosis of myelodysplastic syndromes

This research study has been reviewed and is approved by the Temple University Institutional Review Board and is assigned IRB Protocol #11782.

If you wish to be contacted regarding this study, please email cancer@tuhs.temple.edu and refer to study #11782.

 

Principal Investigator: S. Asim Ali, MD
Primary Contact: Thomas Parsons

Title: A phase III, randomized, double blind, placebo controlled multi-center study of ASA404 in combination with docetaxel in second-line treatment of patients with locally advanced or metastatic (stage IIIb/IV) non-small cell lung cancer (NSCLC).  

Diagnoses: Metastatic non-small cell lung cancer

Study Inclusion Criteria: 

  • Patients who have progressed after first treatment
  • Fulfill all other eligibility criteria

This research study has been reviewed and is approved by the Temple University Institutional Review Board and is assigned IRB Protocol #12087.

If you wish to be contacted regarding this study, please email cancer@tuhs.temple.edu and refer to study #12087.

 

Principal Investigator: Michael E. Bromberg, MD, PhD
Primary Contact: Thomas Parsons

Title: A Phase 2, Mulitcenter, Single-Arm, Open-Label Study To Determine The Efficacy And Safety Of Single-Agent Lenalidomide (Revlimid®) In Patients With Mantle Cell NHL Who Have Relapsed Or Progressed After Treatment With Bortezomib Or Are Refractory To Bortezomib.  

Diagnoses: Mantle Cell Lymphoma

Study Inclusion Criteria: 

  • Disease progressed after treatment
  • Fulfill all other eligibility criteria

This research study has been reviewed and is approved by the Temple University Institutional Review Board and is assigned IRB Protocol #12064.

If you wish to be contacted regarding this study, please email cancer@tuhs.temple.edu and refer to study #12064.

 

Principal Investigator: Aruna Padmanabhan, MD
Primary Contact: Nancy Brunetti

Title: A Phase 3, Randomized, Open-Label, Two-Arm Study of Neratinib Plus Paclitaxel Versus Trastuzumab Plus Paclitaxel as First-Line Treatment of ErbB-2-Positive Locally Recurrent or Metastatic Breast Cancer.  

Diagnoses: Locally Recurrent or Metastatic Breast Cancer

Study Inclusion Criteria: 

  • Breast cancer that is not treatable by surgery and/or radiation
  • Fulfill all other eligibility criteria

This research study has been reviewed and is approved by the Temple University Institutional Review Board and is assigned IRB Protocol #12613.

If you wish to be contacted regarding this study, please email cancer@tuhs.temple.edu and refer to study #12613.

 

Principal Investigator: Aruna Padmanabhan, MD
Primary Contact: Nancy Brunetti

Title: A Randomized, double-blind Placebo-Controlled Trial of Neratinib (HKI-272) After Trastuzumab in Women With Early-Stage HER-2/neu Overexpressed/Amplified Breast Cancer.

Diagnoses: Early-Stage Breast Cancer

Study Inclusion Criteria: 

  • Positive for a specific protein in the cancer
  • Fulfill all other eligibility criteria

This research study has been reviewed and is approved by the Temple University Institutional Review Board and is assigned IRB Protocol #12610.

If you wish to be contacted regarding this study, please email cancer@tuhs.temple.edu and refer to study #12610.

 

Principal Investigator: Deric S. Savior, MD
Primary Contact: Thomas Parsons

Title: A double-blind, randomized, placebo-controlled Phase III study to assess the efficacy of recMAGE-A3 + AS15 Antigen-Specific Cancer Immunotherapeutic as adjuvant therapy in patients with resectable MAGE-A3-positive Non-Small Cell Lung Cancer.  

Diagnoses: Non-Small Cell Lung Cancer

Study Inclusion Criteria: 

  • Undergo surgery for Lung resection
  • Positive for a specific gene in the cancer cells
  • Fulfill all other eligibility criteria

This research study has been reviewed and is approved by the Temple University Institutional Review Board and is assigned IRB Protocol #12983.

If you wish to be contacted regarding this study, please email cancer@tuhs.temple.edu and refer to study #12983.

  

For more information about these or any other clinical trials available at the Temple Cancer Center, please call the Research Office at 215-707-9433.

TOP